Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 9/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30406095 | 1.00 | HTT (0.44) | HTTMEN1KMT2AALDH1A1NPSR1 | |
| Hydrochloric Acid SCHEMBL25270533 | 0.99 | HTT (0.43) | HTTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL25722585 | 0.91 | HTT (0.42) | HTTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL30405901 | 0.90 | HTT (0.48) | HTTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL25220725 | 0.90 | HTT (0.48) | HTTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL25722603 | 0.87 | HTT (0.49) | HTTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL25629403 | 0.86 | HTT (0.46) | HTTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL25229793 | 0.83 | AKT1 (0.42) | HTTMEN1KMT2ACYP3A4HPGD | |
| SCHEMBL19032294 | 0.82 | NCF1 (0.44) | HSD17B10ALOX15 | |
| SCHEMBL25222339 | 0.82 | HTT (0.44) | HTTMEN1KMT2AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107696-A2 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-01-10 | — | — | US | disclosed |
| EP-3394064-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | HTT 3578/4885MEN1 2/4885KMT2A 8/4885 |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | HTT 3578/4885MEN1 2/4885KMT2A 8/4885 |
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | HTT 2985/4885MEN1 2/4885KMT2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.